medigraphic.com
ISSN 1561-3070 (Electronic)

2022, Number 2

<< Back Next >>

Rev Cub Oftal 2022; 35 (2)

Rituximab: effective alternative for peripheral ulcerative kerotopathy

Sánchez-Monroy J, Garcia-Navarro D, Munuera RI

Language: Spanish
References: 13
Page: 1-6
PDF size: 192.02 Kb.


ABSTRACT

The development of biological drugs has allowed optimal control of the ophthalmologic manifestations of autoimmune diseases, the knowledge of new pathogenic pathways and new therapeutic targets, which is leading to a revolution in the medical treatment in numerous entities and where ophthalmology is no exception. We present the clinical case of a patient with poorly controlled rheumatoid arthritis and multisystemic condition. The patient presented a poorly controlled peripheral ulcerative keratopathy that responded to a different biological treatment than the one traditionally used: rituximab.


REFERENCES

  1. Kasper F, Hauser L, Jameson L. Harrison Principios de medicina interna, México DF, McGrawHill 2018, 18Ed, Cap 321: 2738-51.

  2. Artifoni M, Rothschild PR, Brézin A, Guillevin L, Puéchal X. Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(2):108-16.

  3. Knox Cartwright NE, Tole DM, Georgoudis P, Cook SD. Peripheral ulcerative keratitis and corneal melt: a 10-year single center review with historical comparison. Cornea. 2014;33(1):27-31.

  4. Watanabe R, Ishii T, Yoshida M, Takada N, Yokokura S, Shirota Y, Fujii H, Harigae H. Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review. Int J Rheum Dis. 2017;20(2):225-230.

  5. Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am. 2007;33(4):835-54.

  6. Stylianides A, Jones MN, Stewart RM, Murphy CC, Goodson NJ, Kaye SB. Rheumatoid arthritis-associated corneal ulceration: mortality and graft survival. Ophthalmology. 2013;120(4):682-6.

  7. Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am. 2007;33(4):835-54.

  8. Singh G, Salvador VB, Bagchi A, Tushabe R, Abrudescu A. Rheumatoid arthritis-associated corneal ulceration with superimposed infection by methicillin-resistant Staphylococcus aureus: a complicated type of corneal melt. Am J Case Rep. 2014;15:523-5.

  9. Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea. 2005;24(6):742-4.

  10. Albert M, Beltrán E, Martínez-Costa L. Rituximab en queratitis ulcerativa periférica asociada a artritis reumatoide. Arch Soc Esp Oftalmol. 2011;86(4):118-120.

  11. Kraus CL, Culican SM. Use of biologic agents in ocular manifestations of rheumatic disease. Int J Rheumatol. 2012. DOI: https:/doi.org/2012203819

  12. Grupo GUIPCAR de trabajo de la GPC para el Manejo de Pacientes con Artritis Reumatoide. Guía de Práctica Clínica para el Manejo de Pacientes con Artritis Reumatoide. Sociedad Española de Reumatología, 2018;87-88. Disponible en. https://www.ser.es/wp-content/uploads/2018/09/Gu%C3%ADa-de-Pr%C3%A1ctica-Cl%C3%ADnica-para-el-Manejo-de-Pacientes-con-Artritis-Reumatoide.pdf12.

  13. Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016;388(10041):239-47




2020     |     www.medigraphic.com